About Auron Therapeutics
Auron Therapeutics is a biotechnology company that focuses on the development of therapies for solid tumor cancers and hematological malignancies. The company's main service is the development of differentiation-based therapies, which aim to transform the way cancer is treated by targeting cellular plasticity and dysregulated differentiation. These therapies are developed using a proprietary AI-powered platform that integrates large, multi-omic datasets to compare tumor tissue to normal tissues and understand the pathways associated with tumor plasticity and treatment resistance. It was founded in 2018 and is based in Wellesley, Massachusetts.
Latest Auron Therapeutics News
Aug 11, 2023
Illumina CTO, CMO depart By Richard Guy, Biopharma Analyst, and Gunjan Ohri, Data Content Analyst August 10, 2023 11:56 PM UTC Illumina Inc. (NASDAQ:ILMN) announced the departures of CMO Phil Febbo and CTO Alex Aravanis, changes to the C-suite that come weeks after the resignation of CEO Francis deSouza in June and the failure of Chairman John Thompson to win re-election in May. Aravanis is succeeded by VP and Head of Global Advanced Science Steven Barnard; a successor to Febbo has yet to be announced. Illumina also reported its 2Q23 earnings — the company recorded revenue of $1.2 billion, an increase of 1% compared with 2Q22, but cut its non-GAAP diluted EPS guidance to $0.75-$0.90 for fiscal 2023 from $1.25-$1.50. Auron Therapeutics Inc. hired Chris Guiffre as president and COO and appointed Victoria Richon to its board. Richon is CEO of Entact Bio Inc., which she helped launch in December. Auron is developing cancer therapies targeting cellular differentiation pathways discovered via machine learning analyses of multi-omics datasets... BCIQ Company Profiles
Auron Therapeutics Frequently Asked Questions (FAQ)
When was Auron Therapeutics founded?
Auron Therapeutics was founded in 2018.
Where is Auron Therapeutics's headquarters?
Auron Therapeutics's headquarters is located at 7 Norwich Road, Wellesley.
What is Auron Therapeutics's latest funding round?
Auron Therapeutics's latest funding round is Series A.
How much did Auron Therapeutics raise?
Auron Therapeutics raised a total of $61.41M.
Who are the investors of Auron Therapeutics?
Investors of Auron Therapeutics include Polaris Partners, Franklin Berger, BrightEdge, Arkin Bioventures, Eli Lilly and Company and 7 more.